Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies

This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.

Inclusion Criteria:

• Patients with a diagnosis that qualifies them for a DUCBT
• Absence of recent active mold infection
• Adequate organ function
• Availability of eligible donor material

Exclusion Criteria:

• Pregnancy or breastfeeding women and women of child-bearing potential unless two acceptable forms of contraception are being used
• Human immunodeficiency virus (HIV) infection
• Active infection
• Extensive prior chemotherapy
• Prior myeloablative allotransplantation or autologous transplant.